Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Contact The Schall Law Firm As It Initiates An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Phar...
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Phar...
Regeneron Pharmaceuticals Incorporated Investors With Losses Are Encouraged By The Schall Law Firm To Reach Out Amidst Initiation Of An Allegations...
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Phar...
Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Regeneron Pharmaceuticals, Inc. stock has increased over 20% in 2024, trading at $1,071 per share at the time of writing. Regeneron's valuation is high but arguably justified by potential growth, w...
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Investigation Into Claims Against Regeneron Pharmaceuticals Inc Is Initiated By The Schall Law Firm And Investors Who Have Incurred Losses Are Enco...
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharm...
The Schall Law Firm Initiates Probe Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharm...
Impacted Investors Are Invited By The Schall Law Firm To Reach Out As They Start A Probe Into Allegations Against Regeneron Pharmaceuticals Inc
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharm...
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improv...
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on tw...
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Invites Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharm...
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such inves...
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of ...
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year
Related Companies